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I. INTRODUCTION
It has been more than ten years since the Food and Drug Administra-
tion proposed regulations which would have required detailed patient
information for all prescription drugs.' The proposed regulations, in-
tended to promote the safe and effective use of prescription drugs,2 would
have required a manufacturer to supply nontechnical, 3 nonpromotiona 4
information, referred to as patient package inserts, 5 directly to the pa-
tient.6 In response to a directive from President Reagan,7 the final reg-
ulations were withdrawn before implementation."
This note will analyze the need for patient information in satisfying
the tort objectives of informed consent and public safety.9 The note will
then analyze the practical effect of the learned intermediary and informed
consent doctrines upon the manufacturer's and physician's duty to supply
patient information. 0 The note will then analyze the FDA regulations
leading to the proposed patient package insert (PPI) program, the pro-
gram itself, the rationale for the program and the reasons for its revo-
cation.' Finally, the note will present rationale for re-enacting the FDA
regulations.
12
II. PATIENT INFORMATION
A. Introduction
Prescription drugs are dangerous compounds which can cause serious
injury when used improperly and occasionally even when used properly.
A patient taking a prescription drug must be supplied with information
concerning the drug's proper use and symptoms of possible adverse re-
actions if the drug's dangerous properties are to be minimized. Providing
patients with adequate information on the proper use of prescription
drugs and the risks involved in their use satisfies two tort objectives.
' Prescription Drug Products; Patient Labeling Requirements, 44 Fed. Reg.
40,016 (1979) (proposed rule), Prescription Drug Products; Patient Package In-
serts Requirements, 44 Fed. Reg. 60,754 (1979) (final rule, codified at 21 C.F.R.
§ 203 (1981)).
244 Fed. Reg. 40,016 (1979).
3 Id. at 40,016.
4Id. at 40,026.
5 45 Fed. Reg. 60,754 (1980).
644 Fed. Reg. 40,016 (1979).
7Exec. Order No. 12,291, 3 C.F.R. § 1267 (1981), reprinted in 5 U.S.C. § 601
at 431-34 (1982).
8 Prescription Drug Products; Revocation of Patient Package Insert Require-
ments, 47 Fed. Reg. 39,147 (1982).
9 See infra notes 15-61 and accompanying text.
10 See infra notes 62-152 and accompanying text.
1 See infra notes 153-200 and accompanying text.
12 See infra notes 201-217 and accompanying text.
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First, providing adequate patient information satisfies the disclosure re-
quirements of the informed consent doctrine.1 3 Patient information is
essential if the patient's consent is to be knowledgeable and, therefore,
qualify as informed consent.1 4 Second, providing adequate patient infor-
mation aids in limiting the inherently dangerous properties of prescrip-
tion drugs. This decreases the incidence of injury and, consequently
decreases tort liability. Patient information is essential if prescription
drugs are to be used safely and effectively.
B. Informed Consent
A physician must obtain the patient's informed consent before initi-
ating therapy.15 The patient's consent must be knowledgeable if it is to
be true consent.16 Therefore, the patient must be informed of the risks
involved in the use of a particular medication so that the patient may
balance the risks and benefits while taking into account "[his own] per-
sonal values, lifestyle and attitudes towards risk."'1 7 Without adequate
patient information, the patient's consent is not true consent, but merely
acquiescence to the physician's choice of therapy.
1. Balancing the Risks and Benefits
The benefits of prescription drugs range from treating acne to pro-
longing life. The risks of prescription drugs range from mild allergic
reactions resulting in minor discomfort, to thromboembolic disease, 18 re-
sulting in paralysis or death. The severity of the risk, however, does not
necessarily increase with the benefit of the drug. For example, Accutane,' 9
used to treat severe recalcitrant acne, has been associated with major
fetal abnormalities, 20 while insulin, used to treat diabetes, generally
causes only mild allergic reactions.
2
"
1" See infra notes 135-140 and accompanying text.
14 See infra notes 132-134 and accompanying text.
," See infra notes 130-131 and accompanying text.
16 See infra notes 132-133 and accompanying text.
"7 Brushwood & Simonsmeier, Drug Information for Patients, 7 J. LEGAL MED.
279, 282 (1986).
"I Thromboembolic disease refers to disorders caused by a thrombus (blood clot)
blocking a blood vessel; such disorders include myocardial infarction or stroke.
GOODMAN & GILMAN, THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1338, 1435
(5th ed. 1985).
'9 PHYSICIAN'S DESK REFERENCE, 1711 (43rd ed. 1989). Acne is associated with
overactive sebaceous glands. Accutane is Hoffman-La Roche's brand name for
isotretinoin, which inhibits sebaceous gland function. Id. at 1712.
20 Accutane has been associated with major birth defects when taken by women
while pregnant. Id.
21 AMERICAN SOCIETY OF HOSPITAL PHARMACISTS, AFHS-DRUG INFORMATION,
1726-27 (1989). The allergic reactions to insulin include localized itching, redness,
swelling, stinging or warmth at the site of injection.
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One argument presented to justify withholding information from the
patient concerning the risks and benefits of a prescription drug is that
the patient will be intimidated by the possibility of unpleasant side effects
and decide to forego therapy.2  In some circumstances, however, the pa-
tient is more likely to forego therapy if he is not adequately informed of
the risks and benefits of the prescribed medication. For example, medi-
cations used to treat hypertension often have mild but annoying side
effects,2 3 while the disease itself is often symptom free. 24 Adequate patient
information must be provided if the patient is to understand the serious
consequences of untreated hypertension 25 and, therefore, be able to in-
telligently balance the benefits of limiting those consequences against
the risks involved in taking the medication. 26
2. Elective and Non-Elective Drugs
Under the learned intermediary doctrine (which is discussed in more
detail infra) a prescription drug manufacturer need not warn the patient
directly of the risks associated with the use of a prescription drug. 27 The
oral contraceptive drugs, however, are an exception to this general rule.28
In justifying the oral contraceptive exception to the learned intermediary
doctrine, the courts noted that oral contraceptive drugs are used "elec-
tively" and, therefore, the patient is actively involved in the decision to
use the prescription drug.29 Extending this line of reasoning, prescription
drugs can be characterized as "elective" or "nonelective." The "elective"
drugs, for example, would include: the oral contraceptives, used to prevent
22 See infra note 146.
Hypertension is treated with a variety of drugs and drug combinations. The
more common side effects of antihypertensive drugs include sedation, dizziness,
dryness of the mouth and headache. GOODMAN & GiLMAN, supra note 18, at 789
(listing side effects of methyldopa).
24 SLBER, HEART DISEASE, 1120-21 (2d ed. 1987). Hypertension is the chronic
elevation of blood pressure above the range encountered in the general population.
Id. at 212. Hypertension, generally diagnosed by a physician monitoring the
patient's blood pressure, is usually symptom free until the late phases of the
disease when serious pathological consequences begin to appear. Id. at 1120-21.
Hypertension adds to the workload of the heart and arteries. If it continues
for a long time, the heart and arteries may not function properly. This can damage
the blood vessels to the brain, heart and kidneys, resulting in a stroke, heart
failure or kidney failure. U.S. PHARMAcoPEIAL CONvENTION, USPDI-ADvICE FOR
THE PATIENT, 903 (1990) [hereinafter USPDII.
2The FDA, in justifying regulations which would have required patient la-
beling for all prescription drugs, noted that patients with hypertension may not
take their prescribed medication because they do not experience symptoms from
the disease. 44 Fed. Reg. 40,016, 40,020 (1979).
27 See infra notes 74-86 and accompanying text.
2 See infra notes 113-127 and accomoanying text.
See, e.g., MacDonald v. Ortho Pharmaceutical Corp., 394 Mass. 131, -, 475
N.E.2d 65, 69 (1985); Odgers v. Ortho Pharmaceutical Corp., 609 F. Supp. 867,
875 (E.D. Mich. 1985); Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 380 (E.D.
Mich. 1985).
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pregnancy; Rogaine,30 used to treat baldness; and Accutane, 31 used to treat
acne. The "non-elective" drugs, on the other hand, would include: insulin,
used to treat diabetes; Lanoxin, 32 used to treat heart failure; and Di-
lantin, 3 used to treat convulsions.
The need for patient information, however, is not limited only to "elec-
tive" drugs. The FDA has stated that it "does not agree that information
about serious adverse reactions and safety hazards should only be re-
quired for so-called "elective" drug products. The agency is confident that
most patients can participate in the evaluation of the risks and benefits
from drug products. ...
C. Ensuring Safety and Efficacy
Patient information is necessary for all prescription drugs, elective and
non-elective, if they are to be used safely and effectively. Ensuring the
safe and effective use of prescription drugs decreases the incidence of
injury and, thus, tort liability. The safe and effective use of prescription
drugs entails using the drug properly as well as limiting the occurrence
and severity of adverse reactions. Patient information consists of patient
instructions on the proper use of prescription drugs and patient warnings
concerning the risks. Patient instructions can improve patient compliance
and decrease the incidence of drug interactions, thereby decreasing the
occurrence of adverse reactions. 5 Patient warnings can decrease the se-
verity of adverse reactions by allowing earlier recognition of possible
adverse reactions. Patient warnings can also improve patient compliance
by informing patients of frightening but minor side effects.
3o PHYSICIAN's DESK REFERENCE, supra note 19, at 2181. Rogaine is Upjohn
Company's brand name for a 2% topical solution of minoxidil used to promote
hair growth. Id. Minoxidil is also marketed by Upjohn Company in a tablet form
used for treatment of hypertension. Id. at 2171. Patients using the tablet form
of minoxidil to treat hypertension noticed elongation, thickening, and enhanced
pigmentation of body hair. The drug was subsequently tested and approved for
use as a hair growth stimulant.
31 See supra note 19.
32 PHYSICIAN'S DESK REFERENCE, supra note 19, at 778. In congestive heart
failure, cardiac output diminishes due to decreasing contractile strength of the
heart muscle. Lanoxin is Burroughs Wellcome Company's brand name for digoxin,
a cardiac glycoside which increased cardiac output by increasing the contractile
strength of the heart muscle.
I Id. at 1541. Dilantin is Parke Davis's brand name for phenytoin which is
used to prevent and control seizures or convulsions.
44 Fed. Reg. 60,754, 60,764 (1980) (is codified at 21 C.F.R. Part 203).
See, e.g., Malahy, The Effect of Instruction and Labeling on the Number of
Medication Errors Made by Patients at Home, 23 AM. J. Hosp. PHARMACY 282
(1966); Hulka, Kupper, & Cassel, Communication, Compliance and Concordance
Between Physician and Patients with Prescribed Medications, 66 AM. J. PuB.
HEALTH 847 (1976); Morris & Halperin, Effect of Written Drug Information on
Patient Knowledge and Compliance, 69 AM. J. PUB. HEALTH 47 (1979).
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1. Patient Instructions
a. Patient Compliance
Informing the patient of the consequences of improperly taking a pre-
scription drug improves patient compliance, enhancing safety and effi-
cacy. Many prescription medications must be taken on a prescribed dosage
schedule to maintain therapeutic blood levels.3 6 Taking the medication
less often or at a lower dose than prescribed may result in subtherapeutic
blood levels, causing the drug to be ineffective. 37 Taking the medication
more often or at a higher dose than prescribed may result in toxic blood
levels, causing severe adverse reactions. 8 For example, toxic levels of
Dilantin, an anticonvulsant, actually causes convulsions3 9 It is foresee-
able that a patient with toxic blood levels of Dilantin, knowing the med-
ication is for convulsions, may increase the dose of the medication to
counteract convulsions which the medication itself is causing. A patient
aware that toxic levels of Dilantin can actually cause convulsions is more
likely to consult his physician before changing the dose of his medica-
tion.40
b. Drug Interactions
Patient instructions include informing the patient of possible drug in-
teractions. Some medications act differently if taken concurrently with
other medication. 41 Warning the patient of possible drug interactions
can decrease the incidence of adverse reactions, enhancing safety and
3r GOODMAN & GILMAN, supra note 18, at 3-48. Blood levels are measured by
determining the concentration of drug in the blood plasma. The concentration is
generally measured in terms of the number of micrograms of drug per millimeter
of plasma, or mcg/ml. The term therapeutic blood levels refers to drug concen-
tration levels where the drug is effective without being toxic. Id.37 Id.
-Id.
39 GOODMAN & GILMAN, supra note 18, at 452. A good correlation is usually
observed between the total concentration of Dilantin in the blood and its thera-
peutic effect. Control of seizures is generally obtained with concentrations above
1Omcg/ml, while toxic effects generally develop with concentrations above 20mcg/
ml. Id. at 453. See also supra note 36.
40 Dilantin is one of the ten drugs included in a pilot program in FDA regu-
lations which would have required patient package inserts for all prescription
drugs. 45 Fed. Reg. 60,754, 60,758 (1980). See also infra notes 186-190 and ac-
companying text.
41 See, e.g., P. HANSTEN & J. HORN, DRUG INTERACTIONS (6th ed. 1989); FACTS
AND COMPARISONS, DRUG INTERACTION FACTS (1988); WEIBERT & NORCROSS, DRUG
INTERACTIONS INDEX (2d ed. 1988).
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efficacy. Coumadin,42 an anticoagulant,43 is more effective if taken with
aspirin.44 If a patient taking both aspirin and coumadin is cut severely,
the enhanced anticoagulant effect, caused by the aspirin, may make it
difficult to stop the blood loss. 45 Flagyl, 46 an antibiotic, will cause severe
nausea and vomiting if the patient drinks even a minimal amount of
alcohol while taking the medication. 47 Many over the counter cough syr-
ups contain alcohol. 48 A patient taking Flagyl needs to be informed of the
drug's interaction with alcohol as well as the need to check the ingredients
of other medications which may contain alcohol.
2. Patient Warnings
a. Recognition of Adverse Reactions
A patient who is fully informed of the risks of adverse reactions and
the symptoms attending them will be better able to recognize an adverse
reaction before it fully develops, thereby decreasing the severity of the
reaction. 49 For example, a patient taking Chloromycetin, 50 an antibiotic,
42 PHYSICIAN's DESK REFERENCE, supra note 19, at 902. Coumadin is Du Pont
Pharmaceutical's brand name for warfarin sodium, an anticoagulant used to
decrease the clotting ability of the blood and therefore help to prevent harmful
clots from forming in the blood vessels.
An anticoagulant is a drug which prevents blood clots from being formed in
the blood vessels. USPDI, supra note 25, at 1452. Clotting or coagulation is the
body's protective mechanism for stopping blood loss from a severed blood vessel.
PHYSICIAN'S DESK REFERENCE, supra note 19, at 903. See also USPDI, supra
note 25, at 130. A portion of the warfarin in the blood is bound to protein. Protein-
bound warfarin is inactive. Aspirin displaces the warfarin on the protein, con-
verting it to the active unbound form and increasing its therapeutic affect.
4 Coumadin is one of the ten drugs included in a pilot program in FDA reg-
ulations which would have required patient package inserts for all prescription
drugs. See infra notes 186-190 and accompanying text.
46 PHYSICIAN'S DESK REFERENCE, supra note 19, at 2014-15. Flagyl is G.D.
Searle & Company's brand name for metronidazole, an antibiotic used to treat
serious infections.
41 Id. Alcohol should not be consumed while taking metronidazole and for at
least one day afterward. Metronidazole interferes with the metabolism of ethanol
resulting in high concentrations of acetaldehyde in the blood. High blood ace-
taldehyde concentrations may cause abdominal cramps, nausea, vomiting, head-
aches, and flushing.
4 See, e.g., FACTS AND COMPARISONS, DRUG FACTS AND COMPARISONS 836-45
(1989).
49 Thompson, The Drug Manufacturer's Duty to Warn, 13 FLA. ST. U.L. REV.
136, 150 (1985).
The average patient does not see a physician when the early danger signs
appear, because the significance of the danger is not recognized.... In many
clinical circumstances, the patient continues ... taking the drug until se-
rious problems develop which provide the incentive to return to a physi-
cian.... The time delay may spell the difference between safety and
catastrophe.
Id. (quoting M. Dixon, DRUG PRODUCT LIABILITY § 9.02[2], at 9-14.12).
5o PHYSICIAN'S DESK REFERENCE, supra note 19, at 1531. Chloromycetin is the
Parke-Davis's brand name for chloramphenicol, a broad spectrum antibiotic ef-
fective against a wide range of bacterial infections. Due to the possibility of serious
and fatal blood dyscrasisas associated with the use of chloramphenicol, its use is
generally reserved for serious infections only.
1991]
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may ignore a sore throat which is an early symptom of aplastic anemia,51
a rare but life threatening adverse reaction. In justifying regulations
which would have required patient information for all prescription drugs,
the FDA stated: "A patient who is informed about the potential adverse
effects of a drug product is better able to monitor his or her reactions to
the product and to take appropriate action if an adverse effect occurs.
'52
b. Patience Compliance
Warning the patient of possible mild adverse effects can improve patient
compliance. A patient is less likely to discontinue a medication if he is
aware that a minor side effect is not a symptom of a more severe adverse
reaction. For example, Pyridium, 53 used for urinary tract infections,
causes the urine to turn bright orange.5 4 A patient who is not informed
that discoloration of the urine is a normal side effect of the drug may
become alarmed and discontinue the medication.
D. Advantages of Written Patient Information
In order for prescription drugs to be used safely and effectively, the
patient must receive, understand and remember patient information con-
cerning the drug's proper use and possible adverse side effects. 5 The FDA
conducted numerous studies, surveys and public hearings before pro-
mulgating regulations which would have required manufacturers to sup-
ply patient information for all prescription drugs.56 The FDA determined:
51 THE MERK IANuAL 263 (12th ed. 1972). See also USPDI, supra note 25, at
343 (listing the symptoms for blood disorders of which the patient should be
aware). (USPDI-Advice for the Patient is a book providing information on pre-
scription drugs written in lay language. The information provided includes: the
generic name, common brand names, general information on the use of the med-
ication, including: "Before Using This Medicine," "Proper Use of This Medicine,"
"Precautions While Using This Medicine," and "Side Effects of This Medicine."
52 45 Fed. Reg. 60,754, 60,764 (1980).
52 PHYSICIAN's DESK REFERENCE, supra note 19, at 1595. Pyridium is Parke-
Davis's brand name for phenazopyridine, a urinary tract analgesic agent. Urinary
tract infections can be very painful. Phenzopyridine helps to relieve the pain by
acting as a topical analgesic as it is excreted in the urine. The local action of
phenazopyridine is preferable to systemic analgesics which may cause drowsiness.
Id. Phenazopyridine is chemically related to the azo dyes.
5544 Fed. Reg. 40,016, 40,019-20 (1979). The FDA determined that commu-
nicating prescription drug information to the patient can be summarized into five
basic steps: 1) the patient must be exposed to the information; 2) the patient must
pay attention to the information; 3) the patient must understand the information;
4) the patient must accept the information; and 5) the patient must remember
the information.
44 Fed. Reg. 40,016, 40,018 (1979). For a bibliography of surveys and studies
see id. at 40,035-38. See also infra notes 172-180 and accompanying text.
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1) that most patients do not receive adequate information about prescrip-
tion drugs; 2) that information, if provided, is often conveyed in technical
language which the patient is unable to understand; and 3) that patients
tend to forget information provided orally by the doctor.
57
Written information such as patient package inserts are an efficient
and effective means of providing patient information. 8 Verbal informa-
tion is easily forgotten by the patient, while written information such as
patient package inserts can be retained by the patient and referred to at
a later date.
5 9
Providing the patient with supplemental information enhances phy-
sician-patient communication. 0 A well-informed patient is less likely to
be intimidated by the physician and more willing to ask questions. The
physician, aware that the patient is well informed, is likely to be more
attentive to the patient's questions. FDA Commissioner Kennedy stated:
"[K]nowledge raises the quality of discourse between patient and phy-
sician, eliminates unfounded apprehension, increases compliance and
draws the patient into active participation.
6 1
III. PRESCRIPTION DRUG INFORMATION AND THE LEARNED
INTERMEDIARY DOCTRINE
A. The Manufacturer's Duty to Warn and the Learned
Intermediary Doctrine
Ordinarily under products liability law, the manufacturer of a product
has a duty to warn the ultimate user of risks associated with the use of
57 Schwartz, Consumer Warnings for Oral Contraceptives: A New Exception to
the Prescription Drug Rule, 41 FOOD DRUG CosM. L.J. 241, 248 (1986) (citing 44
Fed. Reg. 40,016, 40,020 (1979)).
5844 Fed. Reg. 40,016, 40,021 (1979) (stating that a review of the studies on
written information suggests that it improves communication of important in-
formation to patients). See also, Hulka, Kupper, & Cassel, Communication, Com-
pliance and Concordance Between Physician and Patients with Prescribed
Medications, 66 AM. J. PUB. HEALTH 847 (1976); Morris & Halperin, Effect of
Written Drug Information on Patient Knowledge and Compliance, 69 AM. J. PuB.
HEALTH 47 (1979).
1944 Fed. Reg. 40,016, 40,020 (1979) (stating that studies show that patients
do not remember information that is presented orally).
6045 Fed. Reg. 60,754, 60,760 (1980). The FDA stated that written drug in-
formation will improve communication of important information to patients, will
augment information provided orally and will promote communication between
health care professional and patients.
"I Kennedy, Remarks of the Commissioner of Food and Drugs, 32 FOOD DRUG
CosM. L. J. 384, 386-87 (1977).
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the product.6 2 Prescription drugs, however, are an exception to this gen-
eral rule.63 Manufacturers of prescription drugs need only warn the pre-
scribing physician, who acts as a learned intermediary between the
manufacturer and the consumer.
64
1. Rationale of the Learned Intermediary Doctrine
Prescription drugs may cause injury even when used correctly; however,
the benefits in treating disease generally outweigh the risk of injury.
Prescription drugs, therefore, are considered "unavoidably unsafe".6 5 To
avoid liability, the manufacturer of an "unavoidably unsafe product" must
convey an adequate warning of the risks involved in the use of the product
to the ultimate user.66 The manufacturer "of such products ... is not to
be held to strict liability for unfortunate consequences attending their
use, merely because he has undertaken to supply the public with an
62 Ordinarily under products liability law, the manufacturer of a product is
strictly liable for injuries caused by defects in the product, even if all due care is
exercised in its manufacture. A product may be defective due to: 1) a flaw in the
product (a construction defect); 2) failure to warn (an inadequate warning con-
cerning risks associated with use of the product); or 3) a design defect (a product
design which poses undue risks). PROSSER AND KEETON ON THE LAW OF TORTS
694-702 (5th ed. 1984).
See infra notes 74-85 and accompanying text.
-Id.
RESTATEMENT (SECOND) OF TORTS § 402A comment K (1965): Unavoidably
unsafe products.
There are some products which, in the present state of human knowledge,
are quite incapable of being made safe for their intended and ordinary use.
These are especially common in the field of drugs. [emphasis added] An
outstanding example is the vaccine for the Pasteur treatment of rabies,
which not uncommonly leads to very serious and damaging consequences
when it is injected. Since the disease itself invariably leads to a dreadful
death, both the marketing and the use of the vaccine are fully justified,
notwithstanding the unavoidable high degree of risk which they involve.
Such a product, properly prepared, and accompanied by proper directions
and warnings, is not defective, nor is it unreasonably dangerous. The same
is true of many other drugs, vaccines, and the like, many of which for this
very reason cannot legally be sold except to physicians, or under the pre-
scription of a physician. It is also true in particular of many new or exper-
imental drugs as to which, because of lack of time and opportunity for
sufficient medical experience, there can be no assurance of safety, or perhaps
even of purity of ingredients, but such experience as there is justifies the
marketing and use of the drug notwithstanding a medically recognizable
risk. The seller of such products, again with the qualification that they are
properly prepared and marketed, and proper warning is given, where the
situation calls for it, is not to be held to strict liability for unfortunate
consequences attending their use, merely because he has undertaken to
supply the public with an apparently useful and desirable product, attended
with a known but apparently reasonable risk.
Id.
" Id.
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apparently useful and desirable product, attended with a known but ap-
parently reasonable risk.
67
A prescription drug, "properly prepared and accompanied by proper
directions and warnings, is not defective nor is it unreasonably danger-
ous. '68 [emphasis in original] The prescription drug manufacturer, how-
ever, need not convey the directions and warnings directly to the ultimate
user, the patient.6 9 The courts have determined that the risks associated
with the use of prescription drugs can only be adequately evaluated by
a medical expert.70 Therefore, a special rule known as the learned inter-
mediary doctrine has been applied to prescription drugs. Under the doc-
trine, a prescription drug manufacturer need only warn the prescribing
physician of the risk involved in the prescription drug's use.71 The phy-
sician then acts as a learned intermediary between the manufacturer and
the patient. 72 It is the prescribing physician's duty to warn the patient
of the risks associated with the use of the prescription drug. Liability for
injury resulting from a failure to adequately warn is, therefore, shifted
from the manufacturer to the physician. 73
2. Development of the Doctrine
In Marcus v. Specific Pharmaceuticals, Inc.,74 a 1948 case, the court
held that a prescription drug manufacturer's duty to warn is fulfilled by
giving adequate warning to the prescribing physician.7 5 The language of
the case, however, indicates that the court was primarily concerned with
the concept of privity and the fact that the manufacturer made no rep-
resentations to the patient directly.76 Subsequently, in Love v. Wolf,7 7 a
1964 case, the 13 Court of Appeals for the Third District of California
67 Id.
-Id.
69 See infra notes 77-86 and accompanying text.
70 See infra notes 86-88 and accompanying text.
71 Id.
72 Id.
73 Id.
71 191 Misc. 285, 77 N.Y.S.2d 508 (N.Y. Sup. Ct. 1948). The plaintiff in Marcus
brought action to recover for the death of a 13-month-old child resulting from an
overdose of suppositories administered as prescribed by a physician. Plaintiff
alleged that the manufacturer was negligent in failing to manufacture a sup-
pository for use by very young infants and for not adequately informing physicians
of the proper dosage for very young infants. The court granted defendant man-
ufacturer's motion for dismissal stating: "There is no reason to believe that a
physician would care to disregard his own knowledge of the effects of drugs and
hence of the quantity to be administered, and substitute for his own judgment
that of a drug manufacturer." Id. at __, 77 N.Y.S. at 510.
75 Id. at -, 77 N.Y.S.2d at 509.
76 Id.
77 226 Cal. App. 2d 378,38 Cal. Rptr. 183 (1984). The plaintiff in Love developed
aplastic anemia, a degenerative disease of the bone marrow, after the plaintiff's
physician had prescribed Chlormomycetin, an antibiotic, for a mild infection. The
manufacturer had warned physicians of the risk of aplastic anemia and had
advised physicians that the drug should not be used for minor infections. The
court stated that the manufacturer's warnings were sufficient to shift the duty
of warning the patient to the prescribing physician.
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held that "if adequate warning of potential dangers of a drug has been
given to doctors, there is no duty by the drug manufacturer to insure that
the warning reaches the doctor's patient for whom the drug is pre-
scribed."7
8
Sterlinq Drugs, Inc. v. Cornish7s appears to be the first case to use the
term "learned intermediary" to describe the special role the physician
plays between the patient and the prescription drug manufacturer. 0 In
Sterlinq, the Eighth Circuit Court of Appeals stated that in a case "dealing
with a prescription drug ... the purchaser's doctor is a learned inter-
mediary between the purchaser and the manufacturer."sl
As learned intermediary between the manufacturer and patient, it is
the physician's "duty to inform himself of the qualities and characteristics
of those products which he prescribes. . . and to exercise an independent
judgment, taking into account his knowledge of the patient as well as
the product. 8 2 The physician balances the risks and benefits of the pre-
scription medication for the patient 3 and then decides what facts con-
cerning the risks associated with prescription drugs will be told to the
patient.8 Under the learned intermediary doctrine, "[t]he patient is ex-
pected to and, it can be presumed, does place primary reliance upon that
judgment."8 5
The learned intermediary doctrine has received "virtually unanimous
acceptance and remains the general rule. '88 The court in Reyes v. Wyeth
78 Id. at -, 38 Cal. Rptr. at 193.
79 370 F.2d 82 (8th Cir. 1966). The plaintiff in Sterling developed chloroquine
retinopathy, a degenerative disease of the eye, resulting from the use of Aralen,
a drug used to treat arthritis. The court held that the manufacturer had a duty
to warn doctors of the side effect.
MId. at 85.
I' d.
82 Terhune v. A.H. Robins Co., 90 Wash. 2d 9, __, 577 P.2d 975, 978 (1978).
See, e.g., Reyes v. Wyeth Laboratories, 498 F.2d 1264, 1276 (5th Cir. 1974)
("His [the physician's] is the task of weighing the benefits of any medication
against its potential dangers").
Terhune, 90 Wash. 2d at -, 577 P.2d at 978.
& Id.
In re Certified Questions, 419 Mich. 686, __, 358 N.W.2d 873, 881 (1984)
(Boyle, J., dissenting) (stating: "Other jurisdictions have been virtually unani-
mous in adopting the learned intermediary doctrine for all prescription drugs
.") (footnotes omitted). For a list of cases adopting the learned intermediary
doctrine, see Id. at 881 n.4.
In In re Certified Questions, the United States District Court for the Eastern
District of Michigan certified questions arising from two cases concerning the
manufacturer's duty to warn patients directly of the risks associated with the use
of a prescription drug: Odgers v. Ortho Pharmaceutical, No. 78-70543 (E.D. Mich.
Feb. 18, 1983) (plaintiff alleged that her paralysis was caused by a blood clot
resulting from her use of Ortho Novum, an oral contraceptive); and Granger v.
Sandoz Pharmaceutical, No. 79-40075 (E.D. Mich. Feb. 18, 1983) (plaintiff alleged
injury resulting from the use of Mellaril, an antipsychotic drug).
The majority opinion concluded that the questions could not be decided by
applying existing case law and were best left for the legislature. In re Certified
at 691-92, 697, 358 N.W.2d at 874, 877. The dissenting opinion, adopted by the
Odgers court in its final opinion, argued that a manufacturer of oral contraceptives
does have a duty to warn; however, this duty is not imposed for other drugs. Id.
at 698-718, 358 N.W.2d at 878-87.
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Laboratories8 7 articulated the rationale for the judiciary's acceptance of
the learned intermediary doctrine.
[Wihere prescription drugs are concerned, the manufacturer's
duty to warn is limited to an obligation to advise the prescrib-
ing physician of any potential dangers that may result from
the drug's use. This special standard for prescription drugs is
an understandable exception to the Restatement's general rule
that one who markets goods must warn foreseeable ultimate
users of dangers inherent in his products. Prescription drugs
are likely to be complex medicines, esoteric in formula and
varied in effect. As a medical expert, the prescribing physician
can take into account the propensities of the drug, as well as
the susceptibilities of his patient. His is the task of weighing
the benefits of any medication against its potential dangers.8
3. Decline of the Doctrine
In spite of the judiciary's acceptance of the learned intermediary doc-
trine, the continued viability of the doctrine is in question. 89 As currently
applied, the learned intermediary doctrine substantially overstates the
ability and willingness of the medical community to act as a learned
intermediary. 90 Patients do not receive adequate information concerning
the proper use of prescription medication. Studies indicate that fifty to
sixty percent of the patients using prescription drugs do not take them
properly.9' Studies also indicated that the frequency of medication error
is directly related to the inadequacy of the information received by pa-
tients.92 By placing the duty to warn on the physician who has sole dis-
cretion in deciding what will be told to the patient, the current system
ignores the benefits of having an informed patient.93 "Courts, commen-
tators and legislators have become increasingly cognizant of the obso-
81 98 F.2d 1264 (5th Cir. 1974). See infra notes 98-102 and accompanying text
for a discussion of the case.
Id. at 1276.
81 See infra notes 113-27, 172-93, 212-17 and accompanying text.
Thompson, supra note 49, at 143.
9, 44 Fed. Reg. 40,016, 40,021 (1979). See also Hect, Medicine and the Elderly,
17 FDA CONSUMER 20, 22 (1983) (indicating noncompliance at 50-60%).
92 See, e.g., Malahy, The Effect of Instruction and Labeling on the Number of
Medication Errors Made by Patients at Home, 23 AM. J. HosP. PHARMACY 282
(1966); Hulka, Kupper, & Cassel, Communication, Compliance and Concordance
Between Physician and Patients with Prescribed Medications, 66 AM. J. PUB.
HEALTH 847 (1976); Morris & Halperin, Effect of Written Drug Information on
Patient Knowledge and Compliance, 69 AM. J. PuB. HEALTH 47 (1979).
11 Thompson, supra note 49, at 143.
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lescence of the learned intermediary doctrine '9 4 and have formulated
certain common law and regulatory exceptions to the general rule.
4. The Mass Immunization Exception
The vaccine cases were the first common law exception to the learned
intermediary doctrine. In Davis v. Wyeth Laboratories,95 the plaintiff con-
tracted polio after receiving the Sabin live-virus polio vaccine from a
pharmacist at a immunization clinic.96 The Ninth Circuit Court of Appeals
held that the manufacturer has a duty to warn patients directly when
the vaccine is dispensed "without an individualized balancing by a phy-
sician of the risks involved.
97
In Reyes v. Wyeth Laboratories," the daughter of the plaintiff contracted
polio after receiving the Sabin polio vaccine from a registered nurse at
a county health department.9 9 The manufacturer had included in the drug
package a pamphlet warning of the risks associated with the vaccine, 100
but the nurse did not inform the plaintiff of the risks. 10 1 Relying on the
holding in Davis, the Fifth Circuit Court of Appeals held that the man-
ufacturer has a duty to warn the patient directly when the vaccine is
"dispensed without the sort of individualized medical balancing of the
risks to the vaccinee that is contemplated by the prescription drug ex-
ception."
0 2
In Givens v. Lederle,'0 3 the Fifth Circuit Court of Appeals interpreted
the mass immunization exception to the learned intermediary doctrine
broadly. In Givens, the plaintiff claimed that she had contracted polio
from her child who had been recently vaccinated by a physician.' °4 In
spite of the intervention of the physician between the patient and the
manufacturer, the court held that the mass immunization exception to
the learned intermediary doctrine applied and, therefore, the manufac-
turer "is responsible for taking definite steps to get the warning directly
to the consumer."'1 5 The court noted the physician's testimony that ad-
ministration of the vaccine in a physician's office "really doesn't differ"
from that in an immunization clinic.10
6
- Cody, Products Liability-Food, Drug and Cosmetic Law-Birth Control-A Drug
Manufacturer Who Voluntarily Distributes Patient Pamphlets Has a Duty to Warn
Patients of Dangers Associated with Use of the Drug, 49 U. CrN. L. REv. 517, 528
(1980).
95 399 F.2d 121 (9th Cir. 1968).
Id. at 122-23.
Id. at 131.
9' 498 F.2d 1264 (5th Cir.), cert. denied, 419 U.S. 1096 (1974).
Id. at 1269-70.
10 Id. at 1270.
101 Id.
l 2 Id. at 1277.
103 556 F.2d 1341 (5th Cir. 1977).
'10 Id. at 1343.
105 Id. at 1345.
106Id.
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A recent case, however, refused to extend the mass immunization ex-
ception to a "local program instituted only to immunize certain high
school students who needed the vaccine . ,,.o1 In Walker v. Merck,108 a
1986 case, the plaintiff alleged that her child's blindness had been caused
by a dose of MMR-I1o 9 vaccine administered to the plaintiff while she
was pregnant with the child." 0 The plaintiff had been given the vaccine
by a licensed practical nurse in a clinic-type setting at a local high school
as part of a county-sponsored immunization program."' The Walker court
stated that "[t]his court will not extend the Davis-Reyes-Givens line of
decisions beyond their facts, as the exception to the learned intermediary
rule established for polio cases is quite narrow and highly fact specific. 1 2
5. The Oral Contraceptive Exception
The oral contraceptive drugs were the second exception to the learned
intermediary doctrine. In 1970, prompted by studies indicating that
women using oral contraceptives were more likely to develop throm-
boembolic disease,"13 the FDA enacted regulations requiring manufac-
turers of oral contraceptives to supply warnings directly to the patient.14
Some courts have expanded on this regulatory exception to the learned
intermediary doctrine." 5 These courts have held that manufacturers of
oral contraceptives have a common law duty to warn patients directly
and that the adequacy of that warning is determined by applicable state
law and not by FDA regulations."16
107 Walker v. Merck, 648 F. Supp. 931, 934-35 (M.D.Ga. 1986).
108648 F. Supp. 931.
109 MMR-II is Merck Sharp and Dome's brand name for its Measles, Mumps
and Rubella virus vaccine. PHYsiciAN'S DESK REFERENCE, supra note 19, at 1351.
110 Walker, 648 F. Supp. at 932.
"I1 Id.
'
12 Id. at 934.
113 See Vessey & Doll, Investigation of the Relation Between Use of Oral Con-
traceptives and Thromboembolic Disease, BRIT. MED. J. 199 (1968).114 In 1970, the FDA issued 21 C.F.R. § 130.45 (1970) which required that a
brief warning directed to the patient be included in the oral contraceptive package.
The regulations required a brief statement that the use of oral contraceptives
could cause serious side effects, including abnormal blood clotting. In 1974, the
FDA withdrew 21 C.F.R. § 130.45 and replaced it unchanged with 21 C.F.R. §
310.501. In 1978, the FDA amended 21 C.F.R. § 310.501. The amendment required
that a detailed patient package insert accompany each packet of oral contracep-
tives dispensed and also required that a brief summary of the detailed information
also be included. The brief summary was required to include: 1) a list of con-
traindications; 2) a list of serious side effects; 3) a highlighted statement that
smoking increases the risk of serious side effects; and 4) a statement encouraging
the patient to read the detailed patient package insert. For detailed information
concerning the requirements, see 43 Fed. Reg. 4214 (1978).
"I See infra notes 120-27 and accompanying text.
116 Id.
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I In Lukaszewicz v. Ortho Pharmaceutical Corp. ,l7 the court implied that
manufacturers had a common law duty to warn users of oral contracep-
tives directly of the risks associated with the use of the "pill".118 In an
amended opinion, however, the court stated that it was relying entirely
upon the FDA regulations and not upon a common law duty to warn. 119
Then in MacDonald v. Ortho Pharmaceutical Corporation,120 the Massa-
chusetts Supreme Court held that "the manufacturer of oral contracep-
tives is not justified in relying on warning to the medical profession to
satisfy its common law duty to warn, and that the manufacturer's obli-
gation encompasses a duty to warn the ultimate user."'' The court also
held that supplying the patient with a warning which satisfied FDA
regulations 12 2 did not preclude an action at common law concerning the
adequacy of the warning. 23
In justifying the oral contraceptive exception to the learned interme-
diary doctrine, the court noted: 1) that oral contraceptives are elective
drugs taken by healthy women who are actively involved in the decision
to use them; 2) that there is a high incidence of side effects associated
with the use of oral contraceptives; and 3) that due to the complexity of
the information involved, oral communication by the physician does not
adequately inform the patient.2
4
117510 F. Supp. 961 (E.D. Wis.), modified, 532 F. Supp. 211 (E.D. Wis. 1981).
The plaintiff in Lukaszewicz alleged that the defendant manufactured and sold
Ortho-Novum, an oral contraceptive, in a defective condition unreasonably dan-
gerous to the plaintiff and that as a result of her use of the product she suffered
a cerebral vascular accident. Id. at 962.
118 510 F. Supp. at 965.
119 532 F. Supp. at 211.
120 394 Mass. 131, 475 N.E.2d 65 (1985), cert. denied, 474 U.S. 920 (1985). The
plaintiff in MacDonald alleged that a stroke and resulting injuries were caused
by the manufacturer's failure to warn users of the risk of stroke. Id. at 132-35,
475 N.E.2d at 66-68.
121 Id. at 138, 475 N.E.2d at 70.
122 See supra note 114.
12 394 Mass. at 139, 475 N.E.2d at 70. In justifying its holding the court noted
a statement made by the FDA Commissioner in the preamble to the regulations
amending and expanding the labeling requirements for oral contraceptives. Id.
The Commissioner stated:
The Commissioner does not agree that the imposition of a requirement for
patient labeling will necessarily affect adversely the standard of civil tort
liability which is imposed on drug manufacturers or dispensers. Whether
or not a corporation or individual is to be held liable in a given situation
will depend upon the facts surrounding the manufacture, sale, and use of
the drug product, and on the nature of the injury. It will also depend on the
applicable state law, which the Commissioner notes can be adjusted by state
courts and legislatures in light of the facts presented by patient labeling.
43 Fed. Reg. 4214, 4214 (1978). The court interpreted the Commissioner's state-
ment as supporting the creation of standards under state law which may exceed
the FDA requirements. MacDonald, 394 Mass. at 139, 475 N.E.2d at 70. For a
discussion of the difficulties accompanying individual state standards, see infra
notes 128-29 and accompanying text.
12 394 Mass. at 138, 475 N.E.2d at 69-70.
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In two federal cases 125 decided in the same year as MacDonald, the
District Court for the Eastern District of Michigan also held that man-
ufacturers of oral contraceptives have a common law duty to warn patients
directly of the risks associated with the use of oral contraceptives' 2 and
that supplying a warning which complies with FDA regulations does not
necessarily preclude an action at common law concerning the adequacy
of the warning. 127
Expansion of the oral contraceptive exception to the learned interme-
diary doctrine on a jurisdiction by jurisdiction basis may result in incon-
sistent labelling requirements for oral contraceptive manufacturers. With
the benefit of hindsight, a jury may determine that a manufacturer's
warning was inadequate.' 2 The manufacturer faced with a vague and
nebulous standard which might differ from jury to jury would be forced
to provide warnings concerning every possible risk regardless of its se-
verity or probability. 29 Faced with a lengthy document detailing every
possible consequence, patients are less likely to read the information,
thus defeating the purpose of patient information. A comprehensive reg-
ulatory program, such as that proposed by the FDA (discussed in more
detail infra), could avoid conflicting warning requirements by mandating
that a warning complying with regulations is adequate as a matter of
law.
B. The Physician's Duty to Warn and the Informed
Consent Doctrine
1. Rationale of the Doctrine
"[T]herapy not authorized by the patient may amount to a tort, a com-
mon law battery, by the physician.' 130 To avoid liability, therefore, the
125 Odgers v. Ortho Pharmaceutical Corp., 609 F. Supp. 867 (E.D. Mich. 1985)
(plaintiff alleged that her use of Ortho-Novum, an oral contraceptive manufac-
tured by defendant, caused a blood clot resulting in her paralysis, and that the
defendant had failed to adequately warn of her of the risk); Stephens v. G.D.
Searle & Co., 602 F. Supp. 379 (E.D. Mich. 1985) (plaintiff alleged that her use
of Ovulen, an oral contraceptive, caused her stroke and that defendant was neg-
ligent in not adequately warning her of the risk).
126 Odgers, 609 F. Supp. at 878; Stephens, 602 F. Supp. at 380-81.
127 Odgers, 609 F. Supp. at 877-78 ("I am of the opinion that the FDA's regu-
lation of oral contraceptives was not intended in any way to preclude imposition
of tort liability for failure to warn."); Stephens, 602 F. Supp. at 381 ("It is clear
to this Court that the adequacy of a warning in a products liability case is a
question for the jury.").
128 See supra notes 120-127 and accompanying text. See also Brushwood &
Simonsmeier, supra note 17, at 297-98; Fern, The Decline and Fall of the Learned
Intermediary Doctrine, 28 FOR THE DEFENSE 10, 17 (1986); Knicke, Oral Contra-
ceptives: Heading Into an Era of Unpredictability, Unlimited Liability, and Un-
availability, 19 IND. L. REv. 615, 634-41 (1986).
129 Brushwood & Simonsmeier, supra note 17, at 298.
130 Canterbury v. Spence, 464 F.2d 772, 783 (D.C. Cir. 1972) cert. denied, 409
U.S. 1064 (1972).
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physician must obtain the patient's consent before initiating therapy.'31
True consent is the informed exercise of choice and requires that the
patient have the opportunity to knowledgeably evaluate the therapeutic
options available and the risks involved in those options.132 In order to
ensure that the patient's consent is knowledgeable and to protect the
common law rights of self determination and bodily integrity, the courts
developed the informed consent doctrine.133 The informed consent doctrine
is premised on the fundamental concept that "[elvery human being, of
adult years and sound mind" has a right to determine "what shall be
done with his own body."'13 4
2. The Scope of the Duty to Warn
The informed consent doctrine imposes upon the physician a duty to
warn the patient of the risks associated with a proposed therapy. 35 There
are currently two standards for determining the scope of the duty to
warn.13 6 Under the traditional customary-practice standard, the scope of
the duty to warn is determined by the standard of practice in the medical
community.' 37 The physician is not under a duty to warn unless the med-
ical community has determined that the disclosure is necessary. 38 One
1Id. at 782.
132 Id. at 780.
- Tietz, Informed Consent in the Prescription Drug Context: The Special Case,
61 WASH. L. REV. 367, 370 (1986).
134 Canterbury, 464 F.2d at 780 (quoting Schloendorff v. Society of N.Y. Hosp.,
211 N.Y. 125, 105 N.E. 92, 93 (1914)).
15 For a detailed analysis of the informed consent doctrine in reference to
prescription drugs, see Tietz, supra note 133; Schultz, From Informed Consent to
Patient Choice: A New Protected Interest, 95 YALE L.J. 219 (1985).
136 Tietz, supra note 133, at 368. There are three elements which must be proven
to establish a breach of the duty to warn: 1) whether the physician had a duty
to warn; 2) the scope of that duty; and 3) if the duty was breached, whether the
breach proximately caused the patient's injury (that is, whether the patient would
have refused consent had he been adequately informed). Id. at 371-72.
137 See, e.g., Watkins v. United States, 482 F. Supp. 1006 (M.D. Tenn. 1980);
Finley v. United States, 314 F. Supp. 905 (N.D. Ohio 1970); Carmichael v. Reitz,
17 Cal. App. 3d 958, 95 Cal. Rptr. 381 (1971); Calabrese v. Trenton State College,
162 N.J. Super. 145, 392 A.2d 600 (1978), affd, 82 N.J. 321, 413 A.2d 315 (1980);
Koury v. Follo, 272 N.C. 366, 158 S.E.2d 548 (1968); Boyer v. Smith, 345 Pa.
Super. 66,497 A.2d 646 (1985); Malloy v. Shanahan, 280 Pa. Super. 440,421 A.2d
803 (1980); Kaiser v. Suburban Transp. Sys., 65 Wash. 2d 461, 398 P.2d 14 (1965);
Trogun v. Fruchtman, 58 Wis. 2d 596, 207 N.W.2d 297 (1973). Tietz, supra note
133, at 368 n.8.
138 See Kaiser v. Suburban Transp. Sys., 65 Wash. 2d 461, 464, 398 P.2d 14, 16
(1965) (to determine what warnings are to be given with a prescription drug, a
court should look to what the medical community usually discloses); Natanson
v. Kline, 186 Kan. 393, 350 P.2d 1093, 1106 (1960) ("The duty of the physician
to disclose .. . is limited to those disclosures which a reasonable medical prac-
titioner would make under the same or similar circumstances."). Tietz, supra note
133, at 372 n.28.
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commentator has noted that courts have found the current standard of
practice for physicians in some communities is to keep the patient com-
pletely ignorant. 139
The courts, recognizing the inherent conflict in allowing physicians to
determine for themselves the scope of the duty to warn, developed the
reasonable-patient standard. Under the reasonable-patient standard, the
scope of the physician's duty to warn is determined by what information
a reasonable patient would find material in weighing the risks and ben-
efits of the proposed therapy.
140
Canterbury v. Spence'14 is the leading case establishing a reasonable-
patient standard. In Canterbury, the District of Columbia Court of Ap-
peals found that the duty to warn is independent of the patient's request
for disclosure and that the standard for review is not the standard set by
custom of physicians practicing in the community. 42 The Canterbury
court stated: "Respect for the patient's right of self-determination on
particular therapy demands a standard set by law for physicians rather
than one which physicians may or may not impose upon themselves.'
'14 3
3. The Doctrine and Prescription Drugs
Canterbury dealt with the patient's consent to a surgical procedure.
44
In the case of prescription drugs, however, the courts almost universally
continue to apply the more limited customary-practice standard.145 As
currently applied, the informed consent doctrine overstates the willing-
ness of the medical community to adequately inform patients of the risks
associated with the use of prescription drugs. When prescribing prescrip-
139 Thompson, supra note 49, at 148 (citing M. DIXON, DRUG PRODUCT LIABILITY
§ 7.23, 7-110 (1974)).
40 Tietz, supra note 133, at 368.
141 464 F.2d 772, (D.C. Cir.) cert. denied, 409 U.S. 1064 (1972). The plaintiff in
Canterbury, a youth troubled by back pain, submitted to a laminectomy, an op-
eration to correct the condition. The plaintiff was not informed of the risk of
paralysis incidental to the procedure. The day after the operation the youth fell
from his hospital bed after being left unattended. A few hours after the fall, the
lower half of plaintiffs body was paralyzed. Despite another operation and ex-
tensive medical care the plaintiff remained partially paralyzed. Id. at 776. The
court held that every human being, and thus every medical patient, of adult years
and sound mind has a right to determine what shall be done with his own body
and that true consent is the informed exercise of choice, entailing opportunity to
evaluate knowledgeably the options available and the risks attendant upon each.
Id. at 780.
142 Id. at 783-84. The court held that the physician is under an obligation to
communicate specific information to the patient when required by the exigencies
of reasonable care. Id. at 781. The court stated that the test for determining
whether a particular risk must be disclosed is its materiality to the patient's
decision. Id. at 786-87.
143 Id. at 784.
- Id. at 776.
45 Tietz, supra note 133, at 369. See also supra note 138.
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tion drugs, physicians tend not to inform patients of the less common but
more severe adverse reactions as they believe the patient may be fright-
ened into not taking the medication. 1 6 The current standard of practice
for physicians in some communities is to keep the patient completely
ignorant of the risks involved in the use of prescription drugs. 147 A Gallup
poll taken before FDA regulations required patient package inserts for
oral contraceptives indicated that two-thirds of the women surveyed had
not been told of the risks associated with the use of oral contraceptives. 148
"Optimally for the patient, [disclosure] of a risk would be mandatory
whenever the patient would deem it significant to his decision.... -149
Physicians should be required to inform patients of therapeutic alter-
natives, the risks involved and any other information material to the
patient's informed choice. 10
As currently applied, the informed consent doctrine also overstates the
ability of physicians to adequately inform patients of the risks involved
in the use of prescription drugs. Advances in science have increased the
quantity and complexity of the information available concerning pre-
scription drugs. The sheer volume of drug literature concerning prescrip-
tion drugs is overwhelming and "militates against the physician being
informed of all the hazards of a particular drug .... ."151 Patient infor-
mation in the form of patient package inserts (discussed in more detail
infra), would not result in similar inundation as the patient is not con-
cerned with knowing the risk of a broad spectrum of drugs but only risks
of the drug prescribed. 52
- See, e.g., Plummer v. Lederle Laboratories., 819 F.2d 349, 352, cert. denied,
484 U.S. 898 (1987); Pharmaceutical Mfrs. v. FDA, 484 F. Supp. 1179, 1190 (1980);
Terhune v. A.H. Robins Co., 90 Wash.2d 9, 12, 577 P.2d 975, 979 (1978); Odgers
v. Ortho Pharmaceutical Corp., 609 F. Supp. 867, 878, (E.D. Mich. 1985). See also
Rheingold, Products Liability-The Ethical Drug Manufacturer's Liability, 18 RUT-
GERS L. REV. 947,987 (1964); J. KATZ, THE SILENT WORLD OF DOCTOR AND PATIENT
83 (1984). See also 42 Fed. Reg. 37,636 (1977).
147 See supra note 139.
- Rincke, Oral Contraceptives: Heading Into an Era of Unpredictability, Un-
limited Liability, and Unavailability?, 19 IND. L. REv 615, 625 (1986).
149 Canterbury v. Spence, 464 F.2d 772 (D.C. Cir.), cert. denied, 409 U.S. 1064(1972), 474 F.2d at 787. However, after stating that optimally the patient's sub-jective concerns should be considered, the court then stated such a requirement
would place an undue demand upon the medical profession and, therefore, the
scope of the standard is not subjective as to either the physician or the patient
but remains objective as to the patient's informational needs and with suitable
leeway for the physician's situation. Id.
110 Tietz, supra note 133, at 374.
151 Thompson, supra note 49, at 145.
152 Id.
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IV. FDA REGULATION OF PATIENT INFORMATION
A. Introduction
The FDA has promulgated certain regulatory exceptions to the learned
intermediary doctrine. Beginning in 1968, the FDA determined that cer-
tain drugs were not safe unless labelled with nontechnical, 15 3
nonpromotional 5 4 information provided directly to the patient.1 5 The
FDA regulations challenged the assumption which the courts had been
making in support of the learned intermediary doctrine that prescription
drugs were safe and effective if warnings were supplied only to the pre-
scribing physician.
5 6
B. Patient Warnings
1. Isoproterenol
In 1968, the FDA issued regulations requiring manufacturers to warn
patients directly of the hazards associated with the use of isoproterenol.1
57
Excessive use of isoproterenol, an inhalation drug used by asthmatics,
had been shown to cause severe bronchoconstriction making it more dif-
ficult for the asthmatic to breathe. 158 Noting that isoproterenol is a self-
administered drug whose frequency of use is necessarily determined by
the patient, the FDA promulgated regulations requiring that the inhaler
dispensed to the patient be labeled with a specific warning advising the
patient of the danger associated with excessive use.5 9
2. Oral Contraceptives
In 1970, prompted by studies indicating that women using oral con-
traceptives were more likely to develop thromboembolic disease than
15144 Fed. Reg. 40,016 (1979).
154 Id. at 40,026.
151 Id. at 40,016.
156 Schwartz, Consumer Warnings for Oral Contraceptives: A New Exception to
the Prescription Drug Rule, 41 FOOD DRUG CosM. L.J. 241, 246 (1986).
'1, 33 Fed. Reg. 8812 (1968) (codified at 21 C.F.R. § 201.305).
Id.
' Id. The regulations required that the warning be attached to the medication
container or shipped separately with instructions to the pharmacist to label the
container before dispensing. The required notice stated: "Warning: Do not exceed
the dose prescribed by your physician. If difficulty in breathing persists, contact
your physician immediately." Id.
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nonusers, 16° the FDA issued regulations requiring that a brief patient
warning be inserted in each package of oral contraceptives. 16 ' The reg-
ulations further required that the warning advise the patient that a more
detailed pamphlet was available from the patient's physician. 162 The FDA
noted: 1) that oral contraceptives contain potent steroid hormones; 2) that
they are used for long periods of time by a large number of women who,
for the most part, take them as a matter of choice; and 3) that because
of their indications, they are sometimes used without adequate medical
supervision. 163 The FDA determined that "[tihey represent, therefore, the
prototype of drugs for which well-founded patient information is desir-
able."64
In 1974, under the advice of the National Food and Drug Advisory
Committee, the FDA began a patient prescription drug labeling project
to investigate whether FDA patient labeling should be expanded to other
prescription drugs. 6 5 The FDA discussed the program with interested
parties, interviewed parties likely to be affected by the legislation, re-
viewed the literature concerning patient needs, and conducted research
to evaluate the effectiveness of labeling in communicating information
to patients.16 6
C. Patient Package Inserts
In 1977, the FDA amended the regulations requiring patient warnings
to include the estrogen drugs16 7 and in 1978, revised the patient warning
to include more detailed information. 168 The amended regulations also
'o See Vessey & Doll, Investigation of Relation Between Use of Oral Contra-
ceptives and Thromboembolic Disease, BRIT. MED. J. 199 (1968).
161 35 Fed. Reg. 5962 (1970) (proposed rule), Statement of Policy Concerning
Oral Contraceptive Labeling Directed to Users, 35 Fed. Reg. 9001 (1970) (final
rule, codified at 21 C.F.R. § 130.45). The required warning stated:
Do NOT TAKE THIS DRUG WITHOUT YOUR DOCTOR'S CONTINUED SUPERVISION.
The oral contraceptives are powerful and effective drugs which can cause
side effects in some users and should not be used at all by some women.
The most serious known side effect is abnormal blood clotting which can
be fatal.
35 Fed. Reg. at 9002-03.
162 Id. at 9003.
16 35 Fed. Reg. 5962 (1970).
164 I
.
165 44 Fed. Reg. 40,016, 40,018 (1979).
" Id. at 40,018-19. See also id. at 40,035-38 (bibliography of references).
167 42 Fed. Reg. 37,636 (1977) (codified at 21 C.F.R. § 310.515). The Commis-
sioner concluded that the safe and effective use of drug products containing es-
trogens requires that patients be fully informed of the benefits and risks involved
in the use of these drugs. Id. at 37,641.
15 43 Fed. Reg. 4,214 (1978) (codified at 21 C.F.R. § 310.501). The FDA stated
that the action was taken to provide consumers with expanded labeling infor-
mation reflecting recent reports about the risk of blood clots, other problems of
the circulatory system, cancer and effects upon unborn children associated with
the use of oral contraceptives. Id.
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required that an individual patient package insert be included with each
prescription dispensed.
169
Unlike isoproterenol and oral contraceptives, the estrogen drugs are
not packaged in unit-of-use containers, and the manufacturer must rely
on the pharmacist to dispense the patient warning or patient package
insert. In Pharmaceutical Mfrs. Ass'n v. FDA, 170 drug manufacturers and
pharmaceutical groups challenged the FDA's authority to require patient
package inserts for estrogen drugs. The Third Circuit Court of Appeals
upheld the FDA's regulations based on the FDA's authority to prohibit
misleading labeling of prescription drugs.171 The court determined that
without the patient package insert the estrogen labeling was mislead-
ing.17
2
D. The PPI Program
1. Proposal of the PPI Program
In 1979, the FDA proposed a program requiring mandatory patient
package inserts, written in nontechnical, nonpromotional language for
almost all prescription drugs. 173 The FDA noted that previous patient
labeling regulations had centered on drugs which presented significant
risks but also afforded the patient the ability to participate with the
physician in choosing whether to use the medication.1 7 4 The FDA stated
that it was taking this action to promote the safe and effective use of
prescription drugs by patients and to ensure that patients have the op-
portunity to be informed of the benefits and risks involved in the use of
prescription drugs.
175
The proposal was based on studies showing: 1) that most patients do
not receive adequate information from their physician concerning pre-
scription drugs;176 2) that oral information from the physician is generally
in technical language, not easily understood;177 3) that oral information
1I1 Id. at 4220-21.
170 484 F. Supp. 1179 (D. Del. 1980), affd, 634 F.2d 106 (3d Cir. 1980).
171 634 F.2d at 108.
172 Id.
173 See supra notes 1-6 and accompanying text.
17, 44 Fed. Reg. 40,016, 40,018 (1979).
171 Id. at 40.016.
17 44 Fed. Reg. 40,016, 40,020 (1979). In a national telephone survey of pa-
tients, forty-eight percent of the respondents said that their physician did not
talk to them about their prescription medication. Id. In a study at a clinic that
allowed direct observation of physicians instructing patients, the length of ther-
apy was discussed in only ten percent of the cases, the dosage frequency in only
seventeen percent of the cases, and in seventeen percent of the cases the drug
was never discussed at all. Id.
177 44 Fed. Reg. 40,016, 40,020 (1979). One study revealed, for example, that
a mother did not understand that her child was to be hospitalized when she was
told that the child would have to be "admitted for a work up." Id. Although patients
may not understand what physicians tell them, they may be unwilling to ask for
clarification as they do not want to appear stupid or do not want to bother the
physician with "silly" questions. Id.
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is easily forgotten; 178 and 4) that written patient information is more
effective. 179 The FDA stated that it believes that patient labeling that is
well designed and well written will augment oral communication and
will help overcome the problems which hamper the communication to
patients of important information about prescription drugs. 180
2. Final Regulations Issued
In 1980 under the Carter Administration, the FDA issued final regu-
lations requiring patient package inserts for prescription drugs (the PPI
Program).' 81 The FDA stated that the regulations resulted from the agen-
cy's more than ten years of experience with patient labeling for specific
drugs and that patient package inserts represented a significant initiative
for improving health care. 8 2 The FDA noted that traditionally the extent
of patient knowledge on prescription drugs was not available independ-
ently to patients, but that recently such information is generally available
at bookstores.8 3 Patients, however, are not necessarily aware of the in-
formation's availability nor of its veracity.'8 The FDA stated that it
believes that providing complete and understandable information to pa-
tients can help maximize benefits from prescription drugs, while reducing
their potential harm.185
The final regulations established a pilot program intended to allow the
agency time to evaluate the costs and benefits of patient package inserts
before moving to a full scale program. 8  The pilot program, to be imple-
mented over a three year period, would have required patient package
inserts for ten prescription drugs or drug classes. 187 The regulations re-
178 44 Fed. Reg. 40,016, 40,020 (1979). The FDA noted that although a physician
may provide oral information to the patient, the patient may not be able to process
all of the information. Id. Studies conducted in a clinic show that patients re-
member only about half of the statements made to them about their treatment,
even when interviewed within minutes after leaving the physician's office. Id.
The FDA also noted that the order in which medical information is presented
affects how easily patients remember it. In general, patients tend to remember
what they are told first. In addition, a patient's natural anxiety during an ex-
amination may interfere with the patient's ability to focus attention on the in-
formation provided. Id.
179 44 Fed. Reg. 40,016, 40,020 (1979).
180 Id.
11 Prescription Drug Products; Patient Package Inserts Requirements, 45 Fed.
Reg. 60,754 (1980) (codified at 21 C.F.R. § 203).
182 Id.
183Id.
184 Id.
185Id.
16 45 Fed. Reg. 60,754, 60,756-57 (1980).
187 Id. The drugs or drug classes included: ampicillin, the benzodiazepines,
cimetidine, clofibrate, digoxin, methoxsalen, propoxyphene, phenytoin, thiazides,
and warfarin. These drugs and drug classes were selected because the agency
believed that patient package inserts for these products would significantly en-
hance their safe and effective use. Id. at 60,758.
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quired the manufacturer to prepare and supply patient package inserts,
which were to be dispensed by a pharmacist or other drug dispenser with
the prescription drug.'" The content of the patient package insert was
to include: product identification, route of administration, indications,
contraindications, serious side effects, precautions and general infor-
mation.18 9 "Guideline PPI's," examples of patient package inserts that
complied with the regulations, were described by the regulations for the
ten drugs or drug classes included in the pilot program.19
The regulations stated that the patient package inserts were to sup-
plement the information traditionally provided by the physician and did
not relieve the physician of his duty to provide information to the pa-
tient.19' The regulations also provided that the physician could direct that
the patient package insert not be provided if he believed it would be in
the patient's best interest, although the dispensing pharmacist would
still be required to provide the insert upon the patient's request. 9 2 FDA
Commissioner Kennedy urged physicians to consider "patient labeling
not as an intrusion, but as an educational resource.. . [which] eliminates
unfounded apprehension, [and] increases compliance. 193
3. Stay of the Final Regulations
In 1981 under the new Reagan Administration, the new FDA Com-
missioner Arthur Hayes stayed the effective date of the pilot program.194
Commissioner Hayes issued the stay in response to a Presidential Mem-
orandum requiring agencies in the executive branch to suspend for sixty
days all regulations that were to become effective within a sixty day
period.195 The Presidential Memorandum was followed by Executive Or-
der 12,291, which required the suspension of major regulations to permit
agencies to reconsider their necessity and cost.'9
18 Id. at 60,756.
189 Id. at 60,781-82.
190 Id. at 60,788-817.
"144 Fed. Reg. 40,016, 40,024 (1979).
192 45 Fed. Reg. 60,754, 60,783 (1980) (codified at 21 C.F.R. § 203.26).
193 Kennedy, Remarks of the Commissioner, 32 FoOD DRUG COSM. L.J. 384, 386
(1977).
I" Prescription Drug Products That Require Patient Package Inserts; Tem-
porary Stay of Effective Dates, 46 Fed. Reg. 23,739 (1981) (codified at 21 C.F.R.
§ 203). The stay did not effect the regulations requiring patient package inserts
for the oral contraceptives or the estrogen drugs.
191 Presidential Memorandum of January 29, 1981, 3 C.F.R. 223 (1981).
11 Exec. Order No. 12,291, 3 C.F.R. 127 (1981), reprinted in 5 U.S.C. § 601 at
431-34 (1982).
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4. Revocation of the Program
In September of 1982, the FDA revoked the regulations which would
have established the PPI program.19 7 Although the PPI program was
favored by consumer groups, the FDA withdrew the regulations under
pressure from drug manufacturers and medical associations. 198 The pri-
mary reason given by the FDA for its revocation of the PPI program was
the belief that voluntary programs could accomplish the goal of supplying
patient information and concern that the PPI program would stifle the
voluntary programs currently underway. 19  Subsequent surveys indicate,
however, that patients remain inadequately informed.'0°
V. RATIONALE FOR RE-ENACTING THE PPI PROGRAM
A. Failure of the Voluntary Programs
In revoking the PPI program, the FDA did not revoke its commitment
to providing patient information, nor did it revoke its findings concerning
the effectiveness of written information. 20 1 The FDA revoked the program
because the agency believed that written patient information could be
supplied more cost effectively via voluntary programs such as that pro-
posed by the American Medical Association (AMA).
20 2
The American Medical Association opposed the PPI program on behalf
of physicians who were concerned about how mandatory PPIs would affect
the physician-patient relationship and who desired discretionary rather
than mandatory distribution. 0 3 The AMA initiated a voluntary program
,97Prescription Drug Products; Revocation of Patient Package Insert Require-
ments, 47 Fed. Reg. 39,147 (1982) (codified at 21 C.F.R. § 203).
198 See Public Citizen v. Dep't of Health and Human Servs., No. 81-0820 (D.D.C.
July 31, 1981) (mem.), affd 671 F.2d 518 (D.C. Cir. 1981) (per curium) (Public
Citizen, a consumer group, challenged the FDA stay of the PPI program); Phar-
maceutical Mfrs. Ass'n v. FDA, 484 F. Supp. 1179 (D. Del. 1980), affd, 634 F.2d
106 (3d Cir. 1980) (drug manufacturers and pharmaceutical groups challenged
the FDA'S authority to require patient package inserts). See also 44 Fed. Reg.
40,016, 40,020-21 (1979) (surveys showing consumer support for patient package
inserts); 44 Fed. Reg. 40,016, 40,022-24 (comments against patient labeling and
FDA responses); 47 Fed. Reg. 39,147, 39,148 (1982) (stating that physicians,
manufacturers and distributors of prescription drugs supported revocation of the
regulations while consumers and consumer organizations opposed the revocation).
19 47 Fed. Reg. 39,147, 39,148 (1982).
200 See infra notes 205-207 and accompanying text.
201 47 Fed. Reg. 39,147, 39,148 (1982). The FDA noted that it has repeatedly
affirmed that patients have both a right and need to know about the drugs they
use, and that traditionally they have not had adequate information about pre-
scription drugs available to them. Id. The agency agreed with comments stating
that only written information adequately informs patients and noted that written
information which the patient can retain and refer to later is very useful. Id.
20- Id. at 39,148-49.
m Gifford, From PPI to PIL to PMI: Can the Private Sector Do It Better?, 50
CLEv. CLiac Q. 26 (1983).
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to provide Patient Medication Instruction (PMI) sheets to physicians for
distribution to patients. PMIs cost less than one cent each and are avail-
able for approximately one hundred frequently prescribed drugs or drug
classes.
20 4
Studies indicate, however, that patients are still inadequately in-
formed. In a 1984 survey, only twenty-six percent of the patients sampled
were told about precautions, twenty-three percent were informed about
side effects and only five percent received written information. 20 5 A 1985
survey indicated that seventy-four percent of the patients surveyed were
not informed of side effects,206 and a 1987 survey indicated that four out
of five patients were not informed of potential side effects. 20 7
B. Increased Patient Participation
In today's medically conscious society, patients desire to be active par-
ticipants, not passive recipients of prescription drug therapy.29 Surveys
indicate that patients desire more patient information and are willing to
pay for it. A nationwide survey indicated that forty-nine percent of the
respondents wanted additional information about prescription drugs, par-
ticularly written information in nontechnical language to be dispensed
with the prescription drug.20 9 Another survey of television viewers re-
ported that sixty-nine percent of noon viewers and fifty-seven percent of
evening viewers were willing to pay an additional thirty cents per pre-
scription to receive patient package inserts.210 FDA estimated that patient
package inserts would cost nine cents per prescription if applied to new
and refilled prescriptions and eighteen cents per prescription if applied
only to new prescriptions.
2 1
'
C. Prescription Drug Advertising
Within the last few years, manufacturers have begun to advertise pre-
scription drugs directly to consumers, and television viewers of certain
204 American College of Physicians, Drug Information for Patients, 104 ANNALS
OF INTERNAL MED. 121 (1986).
205 Morris, Grossman, Barkdoll, Gordon & Soviero, A Survey of Patient Sources
of Prescription Drug Information, 74 AM. J. PUB. HEALTH 1161, 1162 (1984) (see
table 2).
216 Gilhooley, Learned Intermediaries, Prescription Drugs, and Patient Infor-
mation, 30 ST. Louis U.L.J. 633, 669 (1986) (citing Morris, Grossman, Barkdoll
& Gordon, A National Survey of Prescription Drug Information Provided to Pa-
tients, table 8 (1986) (copy available at office of St. Louis Univ. Law Journal).
217 Information for Patients About Medicines, 1 LANCET 1077, 1078 (1987).
208 McGarey, Pharmaceutical Manufacturers and Consumer-Directed Infor-
mation-Enhancing the Safety of Prescription Drug Use, 34 CATH. U.L. REV. 117,
143 (1984).
29 44 Fed. Reg. 40,016, 40,020 (1979).
21u 45 Fed. Reg. 60,754, 60,759 (1980).
211 Id. at 60,777.
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cable networks have the opportunity to see advertisements for prescrip-
tions drugs which are supposedly aimed at the physician.212 Prescription
drug advertising is currently opposed by the FDA which is attempting
to establish guidelines for public advertising of prescription drugs. 213
The advent of prescription drug advertising may be used by some courts
to impose a duty on prescription drug manufacturers to warn consumers
directly.2 14 Aggressive marketing techniques and advertisements assur-
ing women of the safety and efficacy of oral contraceptives were two
factors considered by the courts holding that oral contraceptive manu-
facturers have a common law duty to warn consumers directly.21 5 A pre-
scription drug manufacturer who advertises a product is voluntarily
bypassing the physician as learned intermediary. The goal of advertising
is to create demand for a product and even though the physician is nec-
essarily involved in the patient's actual receipt of the prescription drug
product, the manufacturer has departed from its traditional role of dealing
exclusively with the physician. 216 But as noted by the majority opinion
in In re Certified Questions,217 an expansion of such a well settled area of
law is best left to the legislature.
21 8
VI. CONCLUSION
Prompted by the FDA regulations, recent cases have recognized an oral
contraceptive exception to the learned intermediary doctrine, thus im-
posing upon manufacturers of oral contraceptives a common law duty to
warn patients directly.2 9 The courts in these cases reasoned that oral
contraceptives are an "elective" drug with a relatively high incidence of
severe adverse reactions.220 It is foreseeable that the courts will extend
this reasoning to other "elective" drugs and gradually to the "non-elec-
212 Rheingold, The Expanding Liability of the Drug Manufacturer to the Con-
sumer, 40 FOOD DRUG COM. L.J. 135, 139 (1985). Lifetime, a cable service with
an audience of 18.2 million households, has approximately ten hours a week of
physician programming. Id. at 139 n.18. See also Morris & Millstein, Drug Ad-
vertising to Consumers: Effects of Formats for Magazine and Television Adver-
tisements, 39 FOOD DRUG CoMs. L.J. 497 (1984); Novitch, Direct-to-Consumer
Advertising of Prescription Drugs, 39 FOOD DRUG Coms. L.J. 306 (1984).
I's Rheingold, supra note 212, at 139.
214 Id. at 141.
115 See, e.g., Stephens v. G.D. Searle & Co., 602 F. Supp. 379, 380 (E.D. Mich.
1985); Odgers v. Ortho Pharmaceutical Corp., 609 F. Supp. 867. 875 (E.D. Mich.
1985); In re Certified Questions, 419 Mich. 686, 712, 358 N.W.2d 873, 884 (1984)
(Boyle, dissenting) (Boyle's opinion was cited by the courts in Stephens and Odg-
ers).
216 Rheingold, supra note 212, at 141.
217 419 Mich. 686, 358 N.W.2d 873.
218Id. at 691-92, 358 N.W.2d at 874.
219 See supra notes 113-127 and accompanying text.
2120 See supra notes 29, 124 and accompanying text.
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tive" drugs.221 The exceptions are likely to engulf the rule, thus imposing
upon the prescription drug manufacturers a common law duty to warn
patients directly for all prescription drugs.222 Also, the advent of pre-
scription drug advertising, which effectively bypasses the physician as
learned intermediary, may result in the courts' imposing upon prescrip-
tion drug manufacturers a common law duty to warn patients directly. 223
A common law duty to warn is likely to result in labeling requirements
which vary from jurisdiction to jurisdiction. 224 Manufacturers could be
forced to provide warnings concerning every possible risk, resulting in
lengthy warnings which patients are unlikely to read. Administrative
regulation of patient information, such as that proposed by the FDA,
could ensure that the consumers receive patient information in a stand-
ardized, understandable format.
2 25
The regulations should require that prescription drug manufacturers
warn the patient directly where a warning can readily be conveyed in
lay person's language. "A manufacturer's failure to warn the consumer
directly should result in liability for any injury to the consumer proxi-
mately caused by use of the drug. '226 On the other hand, some drugs
present potential for adverse effects not easily communicated in lay lan-
guage. 227 In such cases the physician should have the duty to warn the
patient.22 1 To avoid conflicting labeling requirements imposed by state
law, the regulations should specify that patient package inserts meeting
the standards set by the regulations constitute adequate disclosure by
law. 229 To satisfy the rare instance where non-disclosure is in the patient's
best interest, the regulations may allow the physician to specify that the
patient package insert be withheld.22 0 Although logic dictates that patient
information is best utilized by the patient before he leaves the physician's
221 See supra notes 29-34 and accompanying text. See also Flannagan, Products
Liability: The Continued Viability of the Learned Intermediary Rule as it Applies
to Product Warnings for Prescription Drugs, 20 U. RICHMOND L. REV. 405 (1986);
Fern, The Decline and Fall of the Learned Intermediary Doctrine, 28 FOR THE
DEFENSE 10 (1986).
222 Id.
223See supra notes 212-217 and accompanying text.
224 See supra notes 128-129 and accompanying text.
225 See supra notes 181-193 and accompanying text.
226 Flannagan, supra note 220, at 423.
227 Id.
228 Id.
229 See supra notes 128-29, 223-24 and accompanying text.
20 The FDA allowed for certain exemptions from the patient package insert
dispensing requirements. One of the exemptions allowed the prescribing physician
to direct on the prescription in his or her handwriting that the patient package
insert not be provided to the patient. 45 Fed. Reg. 60,754, 60,783 (1980) (codified
at 21 C.F.R. § 203.26).
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office, practicality in enforcement of the regulations and time constraints
upon the physician dictate that the pharmacist is the best choice as dis-
penser of patient package inserts.
23 1
The patient package insert is a workable solution as attested to by the
fact that they are still required for oral contraceptives.2 2 There is little
doubt that patients are better informed of the risks associated with the
oral contraceptives than the risks associated with other prescription drugs
which do not require patient package inserts. 232 In today's medically con-
scious society, the patient should be regarded as a consumer of a prod-
uct.23 As a consumer, the patient should be an active participant in
prescription drug therapy, not a passive recipient of whatever information
the physician deems best.
235
ALAN R. STYLES
2' The FDA noted: 1) that pharmacists traditionally serve as dispensers of
prescription drugs and are best able to collate, store, and provide labeling to
patients; 2) that physicians prescribe drugs by telephone and may not have the
opportunity to dispense the patient package insert; and 3) that dispenser distri-
bution is more appropriate under FDA'S statutory authority for the regulating
and labeling of drug products. 44 Fed. Reg. 40,016, 40,033 (1979). The FDA stated
that it agrees that physicians have primary responsibility for advising patients
about prescription drugs. Nevertheless, patient labeling is intended to serve pri-
marily as an informational adjunct to the patient-physician encounter to reinforce
and augment the information given to the patient by the physician. 44 Fed. Reg.
40,016, 40,032 (1979). The FDA stated further that although the regulations do
not require a physician who is not the dispenser of the drug to provide the patient
with the patient package insert, physicians are encouraged to present and discuss
the patient package insert with the patient. Id.
22 47 Fed. Reg. 39,147 (1982) (revoking 45 Fed. Reg. 60,754 (1980) (proposed
patient package insert program), but not 43 Fed Reg. 4214 (1978) (labeling re-
quirements for oral contraceptives)).
m A Gallup poll taken before FDA regulations required patient package insert
for oral contraceptives indicated that two-thirds of the women surveyed had not
been told of the risks associated with the use of oral contraceptives. Kincke, supra
note 148, at 625.
-3 McGarey, supra note 208, at 143.
23 5
Id.
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